New biologic KD6005 tested in first human trial for rheumatoid arthritis

NCT ID NCT06213259

Completed Disease control Sponsor: Shanghai Kanda Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new biologic drug called KD6005 in 73 people: first in healthy volunteers, then in patients with rheumatoid arthritis. The main goal was to check safety and how the body processes the drug. It is too soon to know if KD6005 works, but this study is a necessary first step toward possibly finding a new treatment option for rheumatoid arthritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KD6005 (a biologic drug given as an injection)
What this could lead to: If this early study shows KD6005 is safe and well-tolerated, it could pave the way for larger trials to see if it helps control rheumatoid arthritis symptoms.
What could go wrong: This is a very early Phase 1 trial with only 73 participants, focused on safety, not effectiveness. The drug may not work in larger studies or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Peking University People's Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.